Zhou et al., 2021 - Google Patents
Nanoarmour-shielded single-cell factory for bacteriotherapy of Parkinson's diseaseZhou et al., 2021
View PDF- Document ID
- 7766853512997702940
- Author
- Zhou X
- Guo Q
- Guo M
- Li B
- Peng W
- Wang D
- Ming D
- Zheng B
- Publication year
- Publication venue
- Journal of Controlled Release
External Links
Snippet
Cell-based therapy for Parkinson's disease (PD) is a novel and promising approach in recent years. However, exogenous cells are easy to be captured and destroyed by the harsh environment in vivo, so their application prospects have been severely limited. Here, a facile …
- 206010061536 Parkinson's disease 0 title abstract description 61
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Nanoarmour-shielded single-cell factory for bacteriotherapy of Parkinson's disease | |
| Zhan et al. | A dopamine-precursor-based nanoprodrug for in-situ drug release and treatment of acute liver failure by inhibiting NLRP3 inflammasome and facilitating liver regeneration | |
| US10660857B2 (en) | Bacterial compositions for prophylaxis and treatment of degenerative disease | |
| CN105012350B (en) | Probiotics clostridium butyricum bacterial strain | |
| US20220096565A1 (en) | Compositions comprising bacterial strains | |
| KR20180018354A (en) | Nanovesicles derived from Bacillus bacteria and Use thereof | |
| US11793840B2 (en) | Nano-armored single cell product for treating Parkinson's disease through bacteria and a preparation method thereof | |
| JP2023507049A (en) | Strains, compositions thereof, and uses for the treatment of gastrointestinal disorders. | |
| ES2967300T3 (en) | Method to prevent or treat movement disorders with lactic acid bacteria | |
| Yue et al. | Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease | |
| CN114774318B (en) | Application of lactobacillus paracasei in preparation of products for relieving anxiety and depression symptoms | |
| Evrensel et al. | Psychobiotics | |
| CN105012349A (en) | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation | |
| CN114410547B (en) | A strain of Lactobacillus pentosus LPQ1 that can promote 5-HTP secretion and relieve depression and its application | |
| US20210268040A1 (en) | Streptococcus thermophilus cnrz160 strain for the treatment and prevention of intestinal inflammation and associated disorders in an individual | |
| Lee et al. | Neuroprotective effects of agmatine on oxygen-glucose deprived primary-cultured astrocytes and nuclear translocation of nuclear factor-kappa B | |
| US20240382539A1 (en) | Use of intestinal probiotic in preparation of medicament that promotes metabolism of ellagic acid into urolithin a, pharmaceutical composition and use thereof | |
| Zhang et al. | Impact of astaxanthin-enriched algal powder of Haematococcus pluvialis on memory improvement in BALB/c mice | |
| CN115887504B (en) | Application of Bifidobacterium longum CCFM1029 in alleviating Parkinson's disease | |
| Du et al. | Surface nanocoating-based universal platform for programmed delivery of microorganisms in complicated digestive tract | |
| Fang et al. | Cellulose-like chitosan microfibrils facilitate targeted release and enhance the prolonged residence time of quercetin-selenium nanoparticles for Alzheimer’s disease treatment | |
| US12419875B2 (en) | Use of Axitinib and analogs thereof in preparing blood-brain barrier permeability regulator | |
| Wang et al. | An orally biological chemotaxis-guided hypoxia-responsive biomimetic microcapsules for visualizing multi-faceted synergistic therapy of inflammatory bowel disease | |
| JP2007070342A (en) | Composition for improving brain function | |
| CN114699424B (en) | New application of bacteroides fragilis zwitterionic capsular polysaccharide and/or modified zwitterionic capsular polysaccharide |